EP4735480A1 - Multispezifische antikörper mit antigenbindenden domänen zur spezifischen erkennung von c5ar1 und gm-csfr-alpha - Google Patents

Multispezifische antikörper mit antigenbindenden domänen zur spezifischen erkennung von c5ar1 und gm-csfr-alpha

Info

Publication number
EP4735480A1
EP4735480A1 EP24830855.3A EP24830855A EP4735480A1 EP 4735480 A1 EP4735480 A1 EP 4735480A1 EP 24830855 A EP24830855 A EP 24830855A EP 4735480 A1 EP4735480 A1 EP 4735480A1
Authority
EP
European Patent Office
Prior art keywords
seq
amino acid
acid sequence
variant
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP24830855.3A
Other languages
English (en)
French (fr)
Inventor
Chong HE
Wenwu Zhai
Zhiwen Zhou
Michael George Strainic
Ping Yuan
Zuoan YI
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Staidson Beijing Biopharmaceutical Co Ltd
Original Assignee
Staidson Beijing Biopharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Staidson Beijing Biopharmaceutical Co Ltd filed Critical Staidson Beijing Biopharmaceutical Co Ltd
Publication of EP4735480A1 publication Critical patent/EP4735480A1/de
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/624—Disulfide-stabilized antibody (dsFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Peptides Or Proteins (AREA)
EP24830855.3A 2023-06-27 2024-06-27 Multispezifische antikörper mit antigenbindenden domänen zur spezifischen erkennung von c5ar1 und gm-csfr-alpha Pending EP4735480A1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2023102813 2023-06-27
PCT/CN2024/101864 WO2025002221A1 (en) 2023-06-27 2024-06-27 Multi-specific antibodies comprising antigen-binding domains specifically recognizing c5ar1 and gm-csfr alpha

Publications (1)

Publication Number Publication Date
EP4735480A1 true EP4735480A1 (de) 2026-05-06

Family

ID=93937692

Family Applications (1)

Application Number Title Priority Date Filing Date
EP24830855.3A Pending EP4735480A1 (de) 2023-06-27 2024-06-27 Multispezifische antikörper mit antigenbindenden domänen zur spezifischen erkennung von c5ar1 und gm-csfr-alpha

Country Status (3)

Country Link
EP (1) EP4735480A1 (de)
CN (1) CN121816363A (de)
WO (1) WO2025002221A1 (de)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997020048A2 (en) * 1995-11-30 1997-06-05 Bristol-Myers Squibb Company Modified sfv molecules which mediate adhesion between cells and uses thereof
EP1739078A1 (de) * 2005-05-30 2007-01-03 Jerini AG C5a-Rezeptor-Antagonisten
CN116003597A (zh) * 2018-11-27 2023-04-25 舒泰神（北京）生物制药股份有限公司 特异性识别粒细胞-巨噬细胞集落刺激因子受体α的抗体及其用途
TWI869528B (zh) * 2020-01-13 2025-01-11 美商威特拉公司 C5ar1抗體分子及其用途
CN115925918A (zh) * 2021-07-06 2023-04-07 舒泰神（北京）生物制药股份有限公司 特异性识别c5a的抗体及其应用
CN118829654A (zh) * 2021-12-29 2024-10-22 舒泰神(加州)生物科技有限公司 特异性识别C5aR1的抗体及其应用

Also Published As

Publication number Publication date
CN121816363A (zh) 2026-04-07
WO2025002221A1 (en) 2025-01-02

Similar Documents

Publication Publication Date Title
WO2022052974A1 (en) Antibodies specifically recognizing interleukin-4 receptor alpha and uses thereof
WO2022166739A1 (en) Antibodies specifically recognizing thymic stromal lymphopoietin and uses thereof
US20260015423A1 (en) Antibodies specifically recognizing programmed cell death1 ligand 1 and uses thereof
AU2019388584B2 (en) Antibodies specifically recognizing Granulocyte-Macrophage Colony Stimulating Factor Receptor alpha and uses thereof
WO2023129870A2 (en) ANTIBODIES SPECIFICALLY RECOGNIZING C5aR1 AND USES THEREOF
WO2021259160A1 (en) Antibodies specifically recognizing c5a and uses thereof
WO2023016538A1 (en) Antibodies specifically recognizing fcrn and uses thereof
US20250101120A1 (en) Antibodies specifically recognizing fasl and uses thereof
CN118812719A (zh) 特异性结合HBV pre-S1抗原和CD3抗原的多特异性抗体及其应用
JP7693806B2 (ja) シュードモナス属ｐｃｒｖおよびｐｓｌを特異的に認識する抗原結合を含む抗体の組み合わせ及び二重特異性抗体
WO2025002221A1 (en) Multi-specific antibodies comprising antigen-binding domains specifically recognizing c5ar1 and gm-csfr alpha
CN117203230A (zh) 特异性识别c5a的抗体及其应用
EP4524158A1 (de) Antikörper mit spezifischer gdf15-erkennung und verwendung davon
EP4606886A1 (de) Antikörperkombination mit spezifischer bindung an trail oder fasl und bispezifischer antikörper
EP4725501A1 (de) Spezifisch an masp3 bindende antikörper und spezifisch an masp3 und masp2 bindender multispezifischer antikörper
WO2025195443A1 (zh) 特异性结合LIGHT和C5a的多特异性抗体以及组合物及其应用
WO2025190332A1 (zh) 特异性结合nkg2a抗原和pd-l1抗原的多特异性抗体及其应用
CN120699159A (zh) 特异性结合LIGHT和GM-CSFRα的多特异性抗体以及组合物及其应用
CN120682370A (zh) 特异性结合LIGHT和IL-4Rα的多特异性抗体以及组合物及其应用
EA048006B1 (ru) Антитела, специфично распознающие рецептор-альфа гранулоцитарно-макрофагального колониестимулирующего фактора, и их применения
EA049281B1 (ru) АНТИТЕЛА, СПЕЦИФИЧЕСКИ РАСПОЗНАЮЩИЕ PcrV PSEUDOMONAS, И ИХ ПРИМЕНЕНИЕ

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE